OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
SGLT2 Inhibitor Use and Risk of Breast Cancer Among Adult Women with Type 2 Diabetes
Fengge Wang, Michael Hendryx, Nianjun Liu, et al.
Drug Safety (2023) Vol. 47, Iss. 2, pp. 125-133
Closed Access | Times Cited: 10
Fengge Wang, Michael Hendryx, Nianjun Liu, et al.
Drug Safety (2023) Vol. 47, Iss. 2, pp. 125-133
Closed Access | Times Cited: 10
Showing 10 citing articles:
Unveiling the anticancer effects of SGLT-2i: mechanisms and therapeutic potential
Min Sun, Jilei Sun, Wei Sun, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 10
Min Sun, Jilei Sun, Wei Sun, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 10
SGLT2 inhibition and three urological cancers: Up‐to‐date results
Lede Lin, Ning Kang, Liyuan Xiang, et al.
Diabetes/Metabolism Research and Reviews (2024) Vol. 40, Iss. 3
Closed Access | Times Cited: 9
Lede Lin, Ning Kang, Liyuan Xiang, et al.
Diabetes/Metabolism Research and Reviews (2024) Vol. 40, Iss. 3
Closed Access | Times Cited: 9
Research Progress of SGLT2 Inhibitors in Cancer Treatment
Xiaoyong Miao, Jianing Zhang, Weiyan Huang, et al.
Drug Design Development and Therapy (2025) Vol. Volume 19, pp. 505-514
Open Access | Times Cited: 1
Xiaoyong Miao, Jianing Zhang, Weiyan Huang, et al.
Drug Design Development and Therapy (2025) Vol. Volume 19, pp. 505-514
Open Access | Times Cited: 1
Association of SGLT2 Inhibitors with Incident Cancer
Yuta Suzuki, Hidehiro Kaneko, Akira Okada, et al.
Diabetes & Metabolism (2024) Vol. 50, Iss. 6, pp. 101585-101585
Closed Access | Times Cited: 5
Yuta Suzuki, Hidehiro Kaneko, Akira Okada, et al.
Diabetes & Metabolism (2024) Vol. 50, Iss. 6, pp. 101585-101585
Closed Access | Times Cited: 5
The immunohistochemical combination of low SGLT2 expression and high PRDX4 expression independently predicts shortened survival in patients undergoing surgical resection for hepatoblastoma
Yao Liu, Jia Han, Akihiro Shioya, et al.
Diagnostic Pathology (2025) Vol. 20, Iss. 1
Open Access
Yao Liu, Jia Han, Akihiro Shioya, et al.
Diagnostic Pathology (2025) Vol. 20, Iss. 1
Open Access
Exploring the anti-cancer potential of SGLT2 inhibitors in breast cancer treatment in pre-clinical and clinical studies
Yasaman Naeimzadeh, Amir Tajbakhsh, Mahnaz Nemati, et al.
European Journal of Pharmacology (2024) Vol. 978, pp. 176803-176803
Closed Access | Times Cited: 3
Yasaman Naeimzadeh, Amir Tajbakhsh, Mahnaz Nemati, et al.
European Journal of Pharmacology (2024) Vol. 978, pp. 176803-176803
Closed Access | Times Cited: 3
Association between sodium-glucose cotransporter 2 inhibitors and cancer: a systematic review and meta-analysis of randomized active-controlled trials
Bo Xu, Bo-Kyeong Kang, Shaoqian Li, et al.
International Journal of Clinical Pharmacy (2025)
Closed Access
Bo Xu, Bo-Kyeong Kang, Shaoqian Li, et al.
International Journal of Clinical Pharmacy (2025)
Closed Access
Anti-Diabetic Therapies and Cancer: From Bench to Bedside
Dimitris Kounatidis, Natalia G. Vallianou, Ιrene Karampela, et al.
Biomolecules (2024) Vol. 14, Iss. 11, pp. 1479-1479
Open Access
Dimitris Kounatidis, Natalia G. Vallianou, Ιrene Karampela, et al.
Biomolecules (2024) Vol. 14, Iss. 11, pp. 1479-1479
Open Access
Strategies to enhance risk communication about medicines in Malaysia: a Delphi study among multinational experts
Rema Panickar, Zoriah Aziz, Chin Hai Teo, et al.
BMC Health Services Research (2024) Vol. 24, Iss. 1
Closed Access
Rema Panickar, Zoriah Aziz, Chin Hai Teo, et al.
BMC Health Services Research (2024) Vol. 24, Iss. 1
Closed Access
No association between SGLT2 inhibitor use and risk of breast cancer
Reactions Weekly (2023) Vol. 1987, Iss. 1, pp. 8-8
Closed Access
Reactions Weekly (2023) Vol. 1987, Iss. 1, pp. 8-8
Closed Access
